The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
BRCA mutation associated mCRPC previously treated with androgen receptor-directed therapy and a taxane-based ChT
Genitourinary Cancers
Prostate cancer
BRCA mutation
TRITON2
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pemigatinib
-
Single arm (Phase II)
Cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy
Gastrointestinal Cancers
Cholangiocarcinoma
FGFR2 gene fusion or rearrangement
FIGHT-202
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Atezolizumab
Cobimetinib and vemurafenib
Placebo
Treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
Melanoma
Cutaneous Melanoma
BRAF V600
IMspire150
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Capmatinib
-
Single arm (Phase II)
Treatment of adult patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Capmatinib
-
Single arm (Phase II)
For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Atezolizumab
-
Platinum-based chemotherapy
First-line treatment of patients with high PD-L1 expression ≥50% TC or ≥10% IC and who do not have EGFR mutant or ALK-positive NSCLC
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 expression ≥50% TC or ≥10% IC
IMpower110
5
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
1
Pembrolizumab
ChT
Placebo plus ChT
Treatment of locally recurrent unresectable or metastaticTNBC in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy
Breast Cancer
Breast Cancer
Triple-negative, PD-L1 (CPS ≥10)
KEYNOTE-355
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Nivolumab
-
Single arm (Phase II)
Treatment after failure of prior platinum-containing therapy
Genitourinary Cancers
Urothelial Carcinoma
-
CheckMate 275
1
PRELIMINARY SCORE
OS
8
ADJUSTMENTS
FINAL SCORE
F1
5
Osimertinib
-
Placebo
Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR exon 19 deletions or exon 21 (L858R) mutation
ADAURA
A
ADJUSTMENTS
FINAL SCORE
F1
1
Margetuximab
ChT
Trastuzumab plus ChT
Previously treated HER2-positive metastatic breast cancer
Breast Cancer
Breast Cancer
HER2+
SOPHIA
2
PRELIMINARY SCORE
OS
7
ADJUSTMENTS
FINAL SCORE
F1
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.